Answer
Calquence (acalabrutinib maleate) should not be used during pregnancy unless the woman's clinical condition requires acalabrutinib treatment, as animal studies suggest a risk to the foetus.
Sources for this answer
- Calquence 100 mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 8Document updated
Sources checked